Private Equity
The drug developer raised more than $213 million in funding prior to its IPO
1 min read · 01 July 2014
Alta, Atlas, Greatpoint Ventures, RA Capital Management and Third Rock Ventures invested nearly $160 million in the company, which is developing a treatment for obesity
1 min read · 01 July 2014
Investors, including RiverVest, Alta, Novo A/S and others, saw a 3.19x return on their $96 million investemnt
1 min read · 01 July 2014
Investors, including Amgen, CMEA and NEA, invested $56 million in the drug developer that focuses on the gastrointestinal tract
1 min read · 01 July 2014
Benchmark, Charles River Ventures, GGV Capital and other investors put $70 million into the company and realized a 3.84x return at the time of the IPO
1 min read · 13 June 2014
Alta Partners, Burrill & Co, Sr One Ltd and others invested more than $62 million into the company and saw a total return of 2.33x at the time of the IPO
1 min read · 13 June 2014
Domain Associates, Johnson & Johnson and others invested about $19 million and realized a total return of 1.6x at the time of IPO
1 min read · 13 June 2014
Aisling Capital, Care Capital, Kaiser Permanente Ventures and others invested about $92 million in the company and saw a total return of 1.02x at the IPO price
1 min read · 13 June 2014
Fundraising spikes in March, thanks to large fund closings from Founders Fund, Accel and Andreessen Horowitz
2 min read · 01 May 2014
Large acquisitions of venture-backed Nest Labs and Air Watch pushed the M&A totals in February
2 min read · 25 March 2014
